The call highlighted significant advancements in Allogene's clinical trials and financial stability, but was tempered by the report of a Grade 5 event in the ALPHA3 study, raising safety concerns. Overall, the positive developments and strategic advancements suggest a promising outlook, though tempered by specific safety challenges.

Company Guidance

In the second quarter 2025 conference call, Allogene Therapeutics outlined several key metrics and milestones for their ongoing and planned clinical trials. The company reported a cash balance of $302.6 million as of June 30, 2025, with a projected cash runway extending into the second half of 2027. Research and development expenses for the quarter were $40.2 million, including $2.6 million in non-cash stock-based compensation, while general and administrative expenses were $14.3 million, including $6.1 million in non-cash stock-based compensation. The net loss for the quarter was $50.9 million or $0.23 per share. Allogene anticipates a 2025 cash burn of approximately $150 million and full-year GAAP operating expenses of roughly $230 million, excluding potential business development impacts. The company also provided updates on clinical trials, including the ALPHA3 study for cema-cel, which is expected to have a futility analysis in the first half of 2026, and the RESOLUTION study for ALLO-329 in autoimmune diseases, with early clinical results anticipated in the first half of 2026.

Significant Progress Across Portfolio

Advancements in various programs, including cema-cel for large B-cell lymphoma, ALLO-316 for renal cell carcinoma, and ALLO-329 for autoimmune diseases, demonstrating Allogene's scientific and operational momentum.

ALPHA3 Study Design Improvements

Streamlined ALPHA3 study into a 2-arm randomized trial, with more than 50 sites activated in the U.S. and Canada, and additional international expansion underway.

ALLO-316 Advancements

Compelling Phase I data presented at ASCO 2025 for ALLO-316, with alignment on pivotal trial strategy with the FDA and active exploration of partnership opportunities.

Financial Position

As of June 30, 2025, $302.6 million in cash and investments with a cash runway extending into the second half of 2027.

Operational and Financial Discipline

R&D expenses were $40.2 million, G&A expenses $14.3 million, and a net loss of $50.9 million, with expectations of 2025 cash burn at approximately $150 million.

Allogene Therapeutics (ALLO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ALLO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-0.22 / -	-0.32	―	―	―
Aug 13, 2025	2025 (Q2)	-0.27 / -0.23	-0.35	34.29% (+0.12)	―
May 13, 2025	2025 (Q1)	-0.29 / -0.28	-0.38	26.32% (+0.10)	―
Mar 13, 2025	2024 (Q4)	-0.33 / -0.28	-0.51	45.10% (+0.23)	―
Nov 07, 2024	2024 (Q3)	-0.33 / -0.32	-0.37	13.51% (+0.05)	―
Aug 07, 2024	2024 (Q2)	-0.35 / -0.35	-0.53	33.96% (+0.18)	―
May 13, 2024	2024 (Q1)	-0.41 / -0.38	-0.68	44.12% (+0.30)	―
Mar 14, 2024	2023 (Q4)	-0.45 / -0.51	-0.66	22.73% (+0.15)	―
Nov 02, 2023	2023 (Q3)	-0.52 / -0.37	-0.58	36.21% (+0.21)	―
Aug 03, 2023	2023 (Q2)	-0.59 / -0.53	-0.52	-1.92% (-0.01)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ALLO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 13, 2025	$1.04	$1.07	+2.88%
May 13, 2025	$1.13	$0.95	-15.93%
Mar 13, 2025	$1.89	$1.94	+2.65%
Nov 07, 2024	$3.19	$3.08	-3.45%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Allogene Therapeutics Inc (ALLO) report earnings?

Allogene Therapeutics Inc (ALLO) is schdueled to report earning on Oct 30, 2025, Before Open (Confirmed).

What is Allogene Therapeutics Inc (ALLO) earnings time?

Allogene Therapeutics Inc (ALLO) earnings time is at Oct 30, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ALLO EPS forecast?

ALLO EPS forecast for the fiscal quarter 2025 (Q3) is -0.22.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing